Cubist acquiring Adolor for $4.25 per share up front, or a value of about $198M, plus $4.50 in cash per share through a contingent value right (CVR) valued at about $209M

Adolor Corp.

U.S. / Small-Cap Biopharma (<$1 billion)

$208.8m on 10/28/2011 [market cap]

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Cubist Pharmaceuticals Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$2,387.7m on 10/28/2011 [market cap]

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Completed

Sample

01/01/2009

announced

01/01/2009

completed